BC Innovations | Jan 23, 2019
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
BC Extra | Jan 7, 2019
Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
BC Week In Review | Jul 20, 2018
Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
BC Extra | Jul 17, 2018
Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
BC Week In Review | Jun 1, 2018
Clinical News

Ascentage reports Phase I data for APG-1252 in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) reported interim data from 13 evaluable patients with solid tumors, including six with small cell lung cancer (SCLC), in a Phase I trial showing that APG-1252 led...
BC Innovations | Nov 14, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer; prostate cancer Cell culture and mouse studies suggest Bcl-XL inhibitors could help treat glioma, prostate and other cancers harboring the IDH1 R123H mutation. In human glioma and prostate cancer cell lines, cells...
BioCentury | Jan 13, 2017
Finance

Advancing apoptosis

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years. Future Industry Investment Fund led the...
BC Extra | Aug 14, 2015
Financial News

Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors...
Items per page:
1 - 9 of 9